

INFORMATION ONLY

Updated Glassia Implementation FAQ (version 2) Customer Letter # 2024-26

2024-06-05

Dear Colleagues:

The Glassia Implementation FAQ document (attached) has recently been updated to Version 2. This update incorporates significant revisions and additions aimed to better assist the Transfusion Medicine Labs in navigating the implementation process.

The update includes:

- Addition of detailed information in the Transfusion Medicine Lab Section regarding the processing and dispensing of Glassia through labs in all jurisdictions except Alberta and Quebec.
- Modified checklists outlining each partner's roles in the Glassia implementation process.
- Addition of diagrams to illustrate the responsibilities of each partner involved in the process, aligning with the checklist.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This updated FAQ can also be viewed at (https://www.blood.ca/en/hospital-services/customer-services/customer-letters). If you have questions about this FAQ, or if you require it in an accessible format, please contact your local hospital liaison specialist.

This customer letter can also be viewed at www.blood.ca in the "Hospital Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier, Director, Plasma Protein and Related Products Formulary Program